Treatment is recommended for all people living with HIV. It involves taking a combination of antiretroviral drugs. This stops the virus from replicating and allows the immune system to strengthen and fight infections.

HIV treatment: latest news

HIV treatment resources

HIV treatment features

HIV treatment in your own words

HIV treatment news from aidsmap

More news

HIV treatment news selected from other sources

  • AIDS Healthcare Foundation files two lawsuits against Gilead

    Four Californians living with HIV, including one in Marin County, are suing the pharmaceutical company Gilead Sciences over its continued distribution of what they say is a toxic HIV medicine while it kept a safer version of the drug on its lab shelf to turn a higher profit.

    21 May 2018 | The Bay Area Reporter
  • Phase 3 registrational data is not sufficient for roll-out of new ARVs in low- and middle-income countries

    Phase 3 randomised trials for drug approval in high-income countries do not provide sufficient evidence to support the widespread use of new antiretrovirals in low- and middle-income countries (LMICs), where the majority of people with HIV live. Key missing evidence is typically for pregnant women, people with HIV/TB coinfection and people who have not had resistance testing before starting ART.

    15 May 2018 | HIV i-Base
  • Stribild may address 'urgent need' for HIV-2 treatment

    Stribild was well-tolerated and associated with favorable immunovirologic outcomes in ART-naive patients with HIV-2 in West Africa, according to recent data.

    08 May 2018 | Healio
  • Latest DHHS Guidelines for Initial HIV Therapy Now Include 5 Choices — But Really 2 Are Best

    With the important caveat that what follows represents my opinion and not that of these or any other guidelines, one could easily argue that there are really two primary choices here, not five.

    23 April 2018 | NEJM Journal Watch
  • U.S. Guidelines Panel Strongly Recommends Gilead’s HIV Regimen Biktarvy

    The newly approved single-tablet regimen contains the integrase inhibitor bictegravir plus emtricitabine and tenofovir alafenamide.

    04 April 2018 | Poz
  • Ibalizumab-uiyk for HIV: What Pharmacists Should Know

    In March 2018, the FDA approved ibalizumab-uiyk (Trogarzo, Theratechnologies), an injectable CD4-directed post-attachment HIV-1 inhibitor, indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen. With its approval, ibalizumab-uiyk became the first monoclonal antibody to treat HIV. It is also the first HIV therapy with a new mechanism of action to be approved in 10 years.

    27 March 2018 | Pharmacy Times
  • More evidence shows Sustiva increases risk for suicidal behavior

    Patients with HIV on a Sustiva-containing ART regimen had a threefold increased risk for suicidal behavior compared with ART-naive patients, according to recent data published in Clinical Infectious Diseases.

    26 March 2018 | Healio
  • Really Rapid Review — CROI 2018, Boston

    Dr Paul Sax reviews the clinical highlights of CROI 2018.

    12 March 2018 | New England Journal of Medicine Journal Watch
  • FDA approves new HIV treatment for patients who have limited treatment options

    Today, the U.S. Food and Drug Administration approved Trogarzo (ibalizumab-uiyk), a new type of antiretroviral medication for adult patients living with HIV who have tried multiple HIV medications in the past (heavily treatment-experienced) and whose HIV infections cannot be successfully treated with other currently available therapies (multidrug resistant HIV, or MDR HIV).Trogarzo is administered intravenously once every 14 days by a trained medical professional and used in combination with other antiretroviral medications.

    07 March 2018 | FDA
  • Issue Brief: Suboptimal Immune Recovery on Antiretroviral Therapy

    A subset of people on ART experience limited or no recovery of CD4+ T cell counts despite achieving and maintaining undetectable HIV viral loads, and these individuals have an elevated risk of illness and death compared with counterparts who obtain greater CD4+ T cell gains.

    06 March 2018 | TAG
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.